| A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical … NI Cherny, R Sullivan, U Dafni, JM Kerst, A Sobrero, C Zielinski, ... Annals of oncology 26 (8), 1547-1573, 2015 | 1000 | 2015 |
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ... The lancet oncology 12 (3), 236-244, 2011 | 838 | 2011 |
| Prognostic significance of autoimmunity during treatment of melanoma with interferon H Gogas, J Ioannovich, U Dafni, C Stavropoulou-Giokas, K Frangia, ... New England Journal of Medicine 354 (7), 709-718, 2006 | 788 | 2006 |
| Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised … M O’Brien, L Paz-Ares, S Marreaud, U Dafni, K Oselin, L Havel, E Esteban, ... The Lancet Oncology 23 (10), 1274-1286, 2022 | 749 | 2022 |
| ESMO-magnitude of clinical benefit scale version 1.1 NI Cherny, U Dafni, J Bogaerts, NJ Latino, G Pentheroudakis, ... Annals of oncology 28 (10), 2340-2366, 2017 | 715 | 2017 |
| Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome M Voulgarelis, UG Dafni, DA Isenberg, HM Moutsopoulos Arthritis & Rheumatism: Official Journal of the American College of …, 1999 | 668 | 1999 |
| Clinical evolution, and morbidity and mortalityof primary Sjögren's syndrome FN Skopouli, U Dafni, JPA Ioannidis, HM Moutsopoulos Seminars in arthritis and rheumatism 29 (5), 296-304, 2000 | 662 | 2000 |
| Landmark analysis at the 25-year landmark point U Dafni Circulation: Cardiovascular Quality and Outcomes 4 (3), 363-371, 2011 | 557 | 2011 |
| Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer JL Tanyi, S Bobisse, E Ophir, S Tuyaerts, A Roberti, R Genolet, ... Science translational medicine 10 (436), eaao5931, 2018 | 477 | 2018 |
| Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy FG Herrera, C Ronet, M Ochoa de Olza, D Barras, I Crespo, M Andreatta, ... Cancer discovery 12 (1), 108-133, 2022 | 412 | 2022 |
| Zidovudine treatment of the AIDS dementia complex: results of a placebo‐controlled trial JJ Sidtis, C Gatsonis, RW Price, EJ Singer, AC Collier, DD Richman, ... Annals of neurology 33 (4), 343-349, 1993 | 395 | 1993 |
| Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection CD Hall, U Dafni, D Simpson, D Clifford, PE Wetherill, B Cohen, ... New England Journal of Medicine 338 (19), 1345-1351, 1998 | 379 | 1998 |
| Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial M Procter, TM Suter, E De Azambuja, U Dafni, V Van Dooren, ... Journal of Clinical Oncology 28 (21), 3422-3428, 2010 | 353 | 2010 |
| Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis U Dafni, O Michielin, SM Lluesma, Z Tsourti, V Polydoropoulou, D Karlis, ... Annals of Oncology 30 (12), 1902-1913, 2019 | 286 | 2019 |
| Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women MD Kontogianni, UG Dafni, JG Routsias, FN Skopouli Journal of Bone and Mineral Research 19 (4), 546-551, 2004 | 285 | 2004 |
| Breast cancer statistics in the European Union: incidence and survival across European countries U Dafni, Z Tsourti, I Alatsathianos Breast care 14 (6), 344-353, 2019 | 276 | 2019 |
| A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic … S Popat, A Curioni-Fontecedro, U Dafni, R Shah, M O'Brien, A Pope, ... Annals of Oncology 31 (12), 1734-1745, 2020 | 260 | 2020 |
| Prevalence of Sjögren’s syndrome in a closed rural community UG Dafni, AG Tzioufas, P Staikos, FN Skopouli, HM Moutsopoulos Annals of the rheumatic diseases 56 (9), 521-525, 1997 | 249 | 1997 |
| Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta … U Dafni, Z Tsourti, K Vervita, S Peters Lung cancer 134, 127-140, 2019 | 230 | 2019 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 227 | 2017 |
